Recombinant human alpha-fetoprotein and uses thereof
CA 2211324 C · Owner: Martinex R&D Inc. · Inventors: Murgita, Robert A.; Boismenu, Richard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In general, disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal involving administering to the, mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof; methods of inhibiting a neoplasm in a mammal involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an anti-neoplasm fragment or analog thereof; and methods of cell culture involving the use of a, media containing human alpha-fetoprotein or a fragment or analog thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 24, 1996 and granted July 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 24, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 24, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.